Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

To be considered for this study, you would need to have specific type of GEP-NET cancer that has been confirmed by a doctor. Your cancer must be well-differentiated (meaning the cells still look a bit like normal cells) and growing, and can't be removed by surgery. Importantly, your cancer must have grown even after you've already had Lutetium-177 treatment, and it should show up on a special type of scan called an SSTR-PET scan.

You also need to be generally well enough to take part, meaning you can mostly look after yourself. Your kidneys, blood, and liver need to be working properly, which will be checked with blood tests. There are some conditions that would mean you couldn't join. For example, if you've already had certain types of radiation treatment called radioembolisation or if you have serious heart problems like severe heart failure or very high blood pressure that can't be controlled with medicines. Also, if your diabetes is not well managed, you might not be able to participate.

If you join this study, it will involve regular hospital visits, where you'll have check-ups, blood tests, and scans (like SSTR-PET scans) to monitor your health and how your cancer is responding. Some visits might be more frequent at the beginning. You will receive either the new medicine RYZ101 or one of the standard treatments (Everolimus, Sunitinib, Octreotide, or Lanreotide). You won't get to choose which treatment you receive; this is decided randomly, like flipping a coin. You will continue treatment for as long as it is benefiting you and you are tolerating it well. After your treatment ends, there will be follow-up calls or visits to see how you are doing. The total time you're involved in the study can vary, depending on how you respond to the treatment, but it will involve ongoing monitoring.